Deal Library / Pharma BD Deal Intelligence

Biogen Inc. — Pharma Deals

The Pharma Closeout tracks 19 deals, $23.3B in disclosed deal value, 4 with a post-close Outcome Score for Biogen Inc..

Median Critic Score: 78  ·  Median Outcome Score: 60

Best outcome: Biogen Inc. / Reata Pharmaceuticals (73)  ·  Weakest outcome: Biogen Inc. / Bristol-Myers Squibb Company (15)

All 19 deals

• Biogen Inc. / Reata Pharmaceuticals — 2023 · $7.3B · Largely worked — most objectives met.
• Biogen Inc. / Human Immunology Biosciences — 2024 · $1.1B · Largely worked — most objectives met.
• Biogen Inc. / RayThera Inc. — 2026 · $1.0B · Mixed — partial payoff, real shortfalls.
• Biogen Inc. / Bristol-Myers Squibb Company — 2017 · $710M · Did not work — the deal failed to deliver.
• Biogen Inc. / TJ Biopharma Co., Ltd. — 2026 · $850M
• Biogen Inc. / Apellis Pharmaceuticals, Inc. — 2026 · $5.6B
• Biogen Inc. / Alloy Therapeutics, Inc. — 2026
• Biogen Inc. / Vanqua Bio, Inc. — 2025 · $1.1B
• Biogen Inc. / Alcyone Therapeutics, Inc. — 2025 · $85M
• Biogen Inc. / Stoke Therapeutics, Inc. — 2025 · $550M
• Biogen Inc. / City Therapeutics — 2025
• Biogen Inc. / Dayra Therapeutics, Inc. — 2025
• Biogen Inc. / Neomorph Inc. — 2024 · $1.4B
• Biogen Inc. / Alectos Therapeutics Inc. — 2022
• Biogen Inc. / Mirimus, Inc. — 2021
• Biogen Inc. / Bio-Thera Solutions, Ltd. — 2021
• Biogen Inc. / Sage Therapeutics, Inc. — 2020
• Biogen Inc. / Sangamo Therapeutics, Inc. — 2020 · $2.7B
• Biogen Inc. / Nightstar Therapeutics — 2019 · $800M

← Deal Library  ·  Interactive search  ·  How we score deals